Quantcast

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.

Research paper by Maria H MH Gilleece, Myriam M Labopin, Ibrahim I Yakoub-Agha, Liisa L Volin, Gerard G Socié, Per P Ljungman, Anne A Huynh, Eric E Deconinck, Depei D Wu, Jean Henri JH Bourhis, Jean Yves JY Cahn, Emmanuelle E Polge, Mohamad M Mohty, Bipin N BN Savani, Arnon A Nagler

Indexed on: 08 Jul '18Published on: 08 Jul '18Published in: American Journal of Hematology



Abstract

Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1) pre-allogeneic hematopoietic cell transplantation (HCT) may have measurable residual disease (MRD) by molecular and immunophenotyping criteria. We assessed interactions of MRD status with HCT conditioning regimen intensity in patients aged <50 years (y) or ≥50y. This was a retrospective study by the European Society for Blood and Marrow Transplantation registry. Patients were >18y with AML CR1 MRD NEG/POS and recipients of HCT in 2000-2015. Conditioning regimens were myeloablative (MAC), reduced intensity (RIC) or non-myeloablative (NMA). Outcomes included leukemia free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), chronic graft-versus-host (cGVHD) and GVHD-free and relapse-free survival (GRFS). The 2292 eligible patients were categorized into 4 paired groups: <50y MRD POS MAC (N=240) vs RIC/NMA (N=58); <50y MRD NEG MAC (N=665) vs RIC/NMA (N=195); ≥50y MRD POS MAC (N=126) vs RIC/NMA (N=230) & ≥50y MRD NEG MAC (N=223) vs RIC/NMA (N=555). In multivariate analysis RIC/NMA was only inferior to MAC for patients in the <50y MRD POS group, with worse RI (HR 1.71) & LFS (HR 1.554). Patients <50Y MRD NEG had less cGVHD after RIC/NMA HCT (HR 0.714). GRFS was not significantly affected by conditioning intensity in any group. Patients aged <50y with AML CR1 MRD POS status should preferentially be offered MAC allo-HCT. Prospective studies are needed to address whether patients with AML CR1 MRD NEG may be spared the toxicity of MAC regimens. New approaches are needed for ≥50y AML CR1 MRD POS. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

More like this: